Overview

Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer

Status:
Completed
Trial end date:
2000-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Chemosensitizers may increase the effectiveness of a chemotherapy drug by making tumor cells more sensitive to the drug. PURPOSE: Randomized phase III trial to study the effectiveness of chemosensitivity testing to assign treatment for patients with stage III or stage IV ovarian cancer who have undergone surgery.
Phase:
Phase 3
Details
Lead Sponsor:
Swiss Group for Clinical Cancer Research
Treatments:
Carboplatin
Cyclophosphamide
Doxorubicin
Liposomal doxorubicin
Paclitaxel